Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0X1XK
|
|||
Drug Name |
CPC-212
|
|||
Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 1 | [1], [2] | |
Company |
Allergan Parsippany, NJ Chase Pharmaceuticals Washington, DC
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Acetylcholinesterase (AChE) | Target Info | Inhibitor | [1], [2] |
KEGG Pathway | Glycerophospholipid metabolism | |||
Cholinergic synapse | ||||
Panther Pathway | Muscarinic acetylcholine receptor 1 and 3 signaling pathway | |||
Muscarinic acetylcholine receptor 2 and 4 signaling pathway | ||||
Nicotinic acetylcholine receptor signaling pathway | ||||
Pathwhiz Pathway | Phospholipid Biosynthesis | |||
Pathway Interaction Database | ATF-2 transcription factor network | |||
WikiPathways | Monoamine Transport | |||
Biogenic Amine Synthesis | ||||
Acetylcholine Synthesis | ||||
Integrated Pancreatic Cancer Pathway |
References | Top | |||
---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.